UC | Jotup

Greater Sacramento Region Recognized as a National Leader in Equitable Economic Growth by Brookings 2024 Metro Monitor Report

Retrieved on:

Tuesday, April 9, 2024

Employment, Growth, MSA, California State University, UC, BHC, Entrepreneurship, Poverty, Student, GMP, Samsung, Renewable energy

Sacramento, CA, April 09, 2024 (GLOBE NEWSWIRE) -- The 2024 Brookings Metro Rankings , analyzing 10-year economic performance of the country’s 54 largest metros through five key indicators – growth, prosperity, overall inclusion, racial inclusion and geographic inclusion – highlight the Greater Sacramento region's remarkable economic advancements.

Key Points:

Sacramento, CA, April 09, 2024 (GLOBE NEWSWIRE) -- The 2024 Brookings Metro Rankings , analyzing 10-year economic performance of the country’s 54 largest metros through five key indicators – growth, prosperity, overall inclusion, racial inclusion and geographic inclusion – highlight the Greater Sacramento region's remarkable economic advancements.
Notably, the region now boasts the second highest decrease in relative poverty rate in the country (-5%), a testament to the region's improvements in economic equity.
Our region stands as a shining exemplar of accessibility and opportunity for everyone and will only continue to lead by example.”
The Greater Sacramento region is undergoing unprecedented economic momentum.
For more information, access the Brookings Metro Monitor Report: https://www.brookings.edu/articles/metro-monitor-2024/

Perceptyx Announces Winners of 2024 EX IMPACT Awards

Retrieved on:

Thursday, April 4, 2024

TEMECULA, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, today announced the winners of its inaugural EX IMPACT Awards, which honor the ways companies discovered insights, acted on results, and impacted their employees’ experience using Perceptyx’s People Insights Platform.

Key Points:

TEMECULA, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, today announced the winners of its inaugural EX IMPACT Awards, which honor the ways companies discovered insights, acted on results, and impacted their employees’ experience using Perceptyx’s People Insights Platform.
The EX IMPACT Awards recognize people-first organizations making a difference in workplace culture.
“The EX IMPACT Awards recognize organizations that use the Perceptyx People Insights Platform to improve their employees’ experience,” said Kirsten Helvey, Chief Customer Officer at Perceptyx.
“This EX Impact Award showcases the potential this type of strategy carries not only for our organization but others as well!”

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

Retrieved on:

Thursday, April 4, 2024

Toxicity, TNF, Absorption, Ulcerative colitis, Plasma, Tmax, SAN, Patient, UC, MD, Cmax, IBD, Clinical trial, Therapy, Safety, Pharmacokinetics, SAD, JAK, Pharmaceutical industry

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today shared additional positive interim results from the single-ascending dose (SAD) clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap™ device that delivers a proprietary liquid formulation of tofacitinib to the colon. BT-600 is being developed for the potential treatment of patients with ulcerative colitis (UC). The SAD portion of the phase 1 randomized, double-blind, placebo-controlled clinical trial tested the tolerability and pharmacokinetics of BT-600 at 5 mg and 10 mg doses of tofacitinib, compared to placebo, in healthy adult participants.

Key Points:

BT-600 is being developed for the potential treatment of patients with ulcerative colitis (UC).
The SAD portion of the phase 1 randomized, double-blind, placebo-controlled clinical trial tested the tolerability and pharmacokinetics of BT-600 at 5 mg and 10 mg doses of tofacitinib, compared to placebo, in healthy adult participants.
We believe this could lead to better outcomes for patients suffering from UC.”
According to the interim clinical data, all pharmacokinetic endpoints were met in all study participants.
The mean time to reach maximum concentration (Tmax) was 8–10 hours following administration of BT-600, versus 0.5-1.0 hours for conventional oral tofacitinib.

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Retrieved on:

Tuesday, April 2, 2024

Q&A, Primary sclerosing cholangitis, Liver disease, UC, UPMC, KOL, PSC, Doctor of Philosophy, Digestate, CCL24, Clinical trial, Therapy, CMMB, Liver, University of California, Davis, FDA, TEL, Pharmaceutical industry

TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET. To register, click here.

Key Points:

—“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET.
They will discuss the urgent need for new PSC treatments and emerging developments that could facilitate new drug approvals.
Chemomab’s co-founder, CEO & CSO Adi Mor, PhD and CMO Matt Frankel, MD, will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024.
CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that is a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases.

ORBCOMM Announces Christian Mezger as New Chief Financial Officer

Retrieved on:

Tuesday, April 2, 2024

Titan, University, Specialization, Information technology, CFO, Internet of things, Hewlett-Packard, UC, University of California, Riverside, Quaternary, Management

ROCHELLE PARK, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- ORBCOMM Inc., a leading global provider of supply chain IoT technology, announced today that Christian Mezger has joined the company as Chief Financial Officer (CFO).

Key Points:

ROCHELLE PARK, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- ORBCOMM Inc., a leading global provider of supply chain IoT technology, announced today that Christian Mezger has joined the company as Chief Financial Officer (CFO).
With his extensive experience as a global technology executive, Mezger is enthusiastic about the opportunity to help drive team excellence.
Mezger previously served as Executive Vice President and Chief Financial Officer at Anuvu since 2019, where he was responsible for finance, people services, legal, supply chain and information technology.
Before that, he held several other leadership roles, including President and Chief Executive Officer at CMTSU Liquidation (formerly known as Ciber), Executive Vice President and Chief Financial Officer of Ciber and Vice President of Technology Services at Hewlett Packard Company.

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Retrieved on:

Thursday, March 28, 2024

HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.

Key Points:

mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on:

Wednesday, March 27, 2024

Carlsbad, CA, March 27, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update.

Key Points:

“2023 was a transformative year for Palisade Bio as we strategically shifted into the autoimmune, inflammatory, and fibrotic disease space, with the focus on our precision medicine approach in inflammatory bowel disease,” commented J.D.
“As a result of the progress made by our development team, we are on track to launch the Phase 1 study of PALI-2108 by the end of 2024.
Summary of Financial Results for the Year Ended December 31, 2023
As of December 31, 2023, the Company had cash, cash equivalents and restricted cash of $12.5 million.
Net operating loss was $13.1 million for the year ended December 31, 2023 compared to $15.7 million for the year ended December 31, 2022.

Kaplan Surveys: Law Schools Believe the Rankings Have Lost Their Luster, but Pre-Law Students Still Find Them Useful

Retrieved on:

Tuesday, April 9, 2024

Education, Other Education, University, Risk, Harvard University, School, UC, Human, Admission, Student, News, American Bar Association, Lawyer, University of California, Berkeley, Savoy Hotel, Nursing

In total, around 25 percent of law schools no longer actively participate, according to some counts.

Key Points:

In total, around 25 percent of law schools no longer actively participate, according to some counts.
When asked to share their general views of the rankings, law school admissions officers didn’t hold back.
That may even supersede the rankings, for many.”
To speak with a Kaplan law school admissions expert, contact [email protected] .
Among the 86 law schools that participated are 23 of the top 50, as ranked by U.S. News & World Report.

Clinical Communication & Collaboration Market Worth $4.8 billion | MarketsandMarkets™

Retrieved on:

Tuesday, April 9, 2024

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication.

Key Points:

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication.
Moreover, the unique communication needs of physicians, including the requirement for secure and confidential communication channels, further highlights the importance of dedicated physician communication solutions within the clinical communication and collaboration market.
Clinical Communication & Collaboration Market Dynamics:
Key Market Players of Clinical Communication & Collaboration Industry:
Prominent players in the Clinical Communication and Collaboration market include Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US), Baxter International (Hillrom) (US), symplr (US), NEC Corporation (Japan), Spok Inc. (US), Vocera Communications (Stryker) (US), Ascom Holding AG (Switzerland), Everbridge (US), Hidden Brains InfoTech.
Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Clinical Communication and Collaboration market.

Clinical Communication & Collaboration Market Worth $4.8 billion | MarketsandMarkets™

Retrieved on:

Tuesday, April 9, 2024

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication.

Key Points:

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication.
Moreover, the unique communication needs of physicians, including the requirement for secure and confidential communication channels, further highlights the importance of dedicated physician communication solutions within the clinical communication and collaboration market.
Clinical Communication & Collaboration Market Dynamics:
Key Market Players of Clinical Communication & Collaboration Industry:
Prominent players in the Clinical Communication and Collaboration market include Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US), Baxter International (Hillrom) (US), symplr (US), NEC Corporation (Japan), Spok Inc. (US), Vocera Communications (Stryker) (US), Ascom Holding AG (Switzerland), Everbridge (US), Hidden Brains InfoTech.
Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Clinical Communication and Collaboration market.